2025

ANNUAL REPORT

MISSION, NEWS, PROJECTS, PARTNERS, & TRIALS

NATIONAL
PEDIATRIC CANCER
FOUNDATION®

Charity Navigator FOUR-STAR

BBB ACCREDITED CHARITY give.org

Platinum Transparency 2025 Candid.

VERIFIED State Registrations CharityStateRegistration.org COMPLIANCE SHIELD

www.NationalPCF.org

EIN # 59-3097333 CFC # 43259

Dear Friends,
The National Pediatric Cancer Foundation® is headquartered in Tampa, Florida, and our mission is dedicated to funding research to eliminate pediatric cancer. We are one of the highest-rated cancer health charities in the country.

We govern a unique research consortium (called the Sunshine Project™) consisting of physicians and scientists from 38 of the top hospitals in the nation. Our model is highly efficient, nimble, and based on quality, outcome-based research.

For this reason, we ask you to join our effort. The fastest way to better therapies is to leverage NPCF™'s infrastructure to review, fund, and conduct research and transition the promising research to clinical trials without unacceptable roadblocks. Children with cancer need these new therapies immediately.

David Frazer, CEO
National Pediatric Cancer Foundation®

SUNSHINE PROJECT™ RESEARCH IMPACT

- The leading research consortium with national reach addressing multiple types of high-risk pediatric cancers because this problem is greater than just one hospital.
- Top doctors and scientists in 38 pediatric cancer research institutions collaborating to advance the best ideas and science.
- Fast, nimble, non-bureaucratic, out-of-the box, streamlined research with focused funding.
- National network of patient accruals versus one market/region.
- No government funding.
- One of the highest-rated cancer charities in the nation.
- $38 million in research funding over the past 12 years with success in multiple drug combinations therapies & identification.
- Multiple current clinical trials and 30+ translational studies underway.

OUR PARTNER INSTITUTIONS

- Nemours/A.I. duPont Hospital for Children Wilmington, DE
- Arkansas Children's Hospital Little Rock, AR
- Atrium Health | Levine Cancer Institute Charlotte, NC
- Children's Healthcare of Atlanta Atlanta, GA
- Children's Hospital Colorado Aurora, CO
- Children's Hospital of Los Angeles Los Angeles, CA
- Children's Hospital of Philadelphia Philadelphia, PA
- Children's National Medical Center Washington, DC
- Cleveland Children's Clinic Cleveland, OH
- Connecticut Children's Medical Center Hartford, CT
- Duke University Health System/ Duke Cancer Institute Durham, NC
- Corewell Health Helen DeVos Children's Hospital St. Petersburg, FL
- Johns Hopkins All Children's Hospital St. Petersburg, FL
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore, MD
- University of Texas MD Anderson Cancer Center Houston, TX
- Moffitt Cancer Center Tampa, FL
- Children's Hospital at Montefiore Bronx, NY
- Pediatric Oncology Branch, NCI, NIH Bethesda, MD
- Nationwide Children's Hospital Columbus, OH
- Nemours Children's Clinic Jacksonville, FL
- Nemours Children's Hospital Orlando, FL
- Phoenix Children's Hospital Phoenix, AZ
- Primary Children's Medical Center Salt Lake City, UT
- Roswell Park Comprehensive Cancer Center Buffalo, NY
- Seattle Children's Hospital Seattle, WA
- St. Joseph's Children's Hospital Tampa, FL
- Stanford University Palo Alto, CA
- Children's of Alabama Birmingham, AL
- University of Chicago Chicago, IL
- Stead Family Children's Hospital Iowa City, IA
- University of Florida/UF Health Shands Hospital Gainesville, FL
- UK Healthcare | Kentucky Children's Hospital Lexington, KY
- Sylvester Comprehensive Cancer Center Miami, FL
- UNC Lineberger Comprehensive Cancer Center Chapel Hill, NC
- Children's Medical Center Dallas, TX
- Vanderbilt-Ingram Comprehensive Cancer Center Nashville, TN St. Louis
- Children's Hospital St. Louis, MO
- Weill Cornell Medicine New York City, NY

RESEARCH PROJECTS AND TRIALS

1. **Evolutionary inspired therapy for newly diagnosed, metastatic, Fusion Positive Rhabdomyosarcoma**
   Metastatic, fusion positive rhabdomyosarcoma (RMS) have a poor outcome which is worsened with additional risk factors commonly called the Oberlin criteria. Patients that meet all 4 Oberlin criteria have an Event Free Survival (EFS) of less than 20% at 2 years. All therapeutic arms on this study are designed to meet the same primary aim of improving the 3 year event free survival from 6% to 35% for these patients.

2. **Blood based biomarkers for minimal residual disease detection in Pediatric Sarcomas**
   The purpose of this study is to see if detecting cell-free plasma tumor DNA (PTDNA) and circulating tumor cells (CTC) can predict recurrence of disease in patients who are in radiographic permission 2-3 weeks after treatment. Plasma tumor dna (PTDNA) is free floating DNA from the tumor found in the blood stream and circulating tumor cells.

3. **A Multi-Institution Study of TGFβ imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination with Gemcitabine and Docetaxel in Patients with Relapsed or Refractory Pediatric Bone and Soft Tissue Sarcomas: The TiNKS Trial**
   The purpose of this trial is to determinethe safety of the addition of adoptive transfer of universal donor, TGFβ imprinted (TGFβi), expanded NK cells to gemcitabine/docetaxel (GEM/DOX) for treatment of relapsed and refractory sarcomas and to determine the 6 month progression free survival achieved wtih this treatment.

4. **Feasibility of Generating Novel Translational and Therapeutic Strategies based on a Multicenter, Pediatric and AYA Evolutionary Tumor Board (pedsETB)**
   Pediatric Evolutionary Tumor Board(pedsETB) is a multidisciplinary forum to approach an individual patient's cancer and propose additional ideas for care. The pedsETB will gather together disciplines not often engaged in cancer work and use insights from evolution to optimally model, research, and impact pediatric cancer outcomes. Strategies from pedsETB's predecessor have been instrumental in the design of several of NPCF's most recent clinical trials

RESEARCH PROJECTS AND TRIALS

5. Evaluation of Digoxin for relapsed Non-WNT, Non-SHH Medulloblastoma (Phase 2 Study)

This trial will evaluate the efficacy of Digoxin in treating patients with relapsed non-SHH, non-WNT medulloblastoma and to determine if digoxin improves progression free survival at 4 months after initiation of study treatment in this patient population.

6. Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes

This trial will test our ability to administer frequently changing chemotherapy regimens, called sequential second strikes, to patients with widely metastatic Ewing sarcoma to stop its development of resistance to chemotherapy and improve cure rates

7. RNA Lipid particles targeting pediatric recurrent intracranial malignancies and other systemic solid tumors

This trial tests the safety, immune effects, and potential effectiveness of RNA-loaded lipid nanoparticles (RNA-LP) vaccines in patients with recurrent pediatric high-grade glioma (PHGG), a type of bone cancer, and recurrent osteosarcoma (OSA), a type of bone cancer.

8. Open-Label, Cohort-Sequential Dose-Escalation and Dose-Confirmation Phase 1-2 Clinical Trial

This trial will evaluate the safety and efficacy of Domatinostat in combination with Sirolimus in adolescents and adults with relapsed, refractory sacroma and osteosarcoma. This trial tests the safety and effectiveness of two drugs, Domatinostat and Sirolimus, used together in patients with osteosarcome and other sarcomas that have come back or do not respond to other treatments.

43 CHALLENGE DOCTORS

1. **Pediatric Oncologist, Dr. Dan Weiser from Montefiore Einstein Cancer Center / Children's Hospital at Montefiore**
   Dr. Weiser's science has identified a novel technology that can control and degrade a specific c-MYC gene (known as the master regulator) across many types of cancer. Since c-MYC is detected in 74% of human cancers, the ability to degrade and attack this common link has the potential to transform the treatment of cancer.

2. **Dr. Keisuke Iwamoto from David Geffen School of Medicine at UCLA**
   Dr.Iwamoto is a renowned expert on radiation and its use in cancer treatment. Using his studies into the radiological effects of nuclear bombs on survivors during WWII, he will use quantum mechanics to precisely target specific tumor cells without harming normal cells, revolutionizing cancer treatment. The method uses conventional clinical procedures in a novel combination within a weak magnetic field, akin to a refrigerator magnet's, such that if successful it could be introduced into any hospital without major infrastructural, financial, or procedural difficulty to treat children and even infants with medulloblastoma, the most common childhood brain cancer.

3. **Dr. Gregory Sullivan from Paratope Bio, LLC**
   The work of Dr. Sullivan and Paratope Bio, LLC will leapfrog traditional drug development to produce a smart set of innate antibodies that have limited toxicity and would specifically attack pediatric tumors.

IN FISCAL YEAR 2024 - 2025

Financial Highlights for fiscal year 2024/2025:

- Public Support and Revenue (Net of event direct expenses) = **$4,748,979**
- Ending Net Assets = **$5,143,288**
- Program Expenses = **$5,132,533**
- Management & General = **$217,874**
- Development & Community Support= **$356,020**
- Total Operational Expenses = **$5,706,427**

Specific details & additional accomplishments are provided on our website, to include:

- IRS form 990
- Annual financial statements (income & expense)
- Listing of activities/accomplishments

Our Board Members: BB Abbott, James Bassil, David Boyington, Chris Carrere, Carrie Charles, Melissa Dunkel, John Fitzpatrick, Chad Harrod, Ricky Huff, Joseph Lamphier, Jay Langford, Michael Levin, Jeff Maxwell, Mark McHugh, Angela North, Jeremy Persinger, Marco Schnabl, Dawn Siler-Nixon, Al Silva, Alex Sullivan, Ashlie Teeling, and Michael Weigner.

NATIONAL PEDIATRIC CANCER FOUNDATION® MISSION

The National Pediatric Cancer Foundation is dedicated to funding research to eliminate childhood cancer. Our focus is to find less toxic, more effective treatments through a unique collaborative research initiative called the Sunshine Project.

89¢ of every dollar we spend directly supports our mission. We have been giventhe highest ratings a nonprofit can receive for financial transparency and accountability.

NPCF™ RATINGS

Donors can be confident their dollars are spent effectively, as the NPCF has received a perfect 4-star, 100% rating for financial health and transparency.

Charity Navigator FOUR-STAR

BBB ACCREDITED CHARITY give.org

Platinum Transparency 2025 Candid.

VERIFIED State Registrations CharityStateRegistration.org COMPLIANCE SHIELD

NATIONAL
PEDIATRIC CANCER
FOUNDATION®

NationalPCF.org

5550 West Executive Drive, Suite #200, Tampa, FL 33609

(813) 269-0955

EIN# 59-3097333
CFC# 43259

Donate Now
NationalPCF.org/donate